Tag - CNTA

Markets

Leerink ups Centessa PT to $11 from $6 on pipeline prospects

Leerink Partners raised its price target for Centessa Pharmaceuticals (NASDAQ:CNTA) to $11 from $6, and reiterated an “outperform” rating, citing an improved outlook for its pipeline. The stock closed at $6.62 on Aug...

August 15, 2023

Feature

Centessa focused on asset-centric, patient-centric drug development

Centessa Pharmaceuticals (NASDAQ:CNTA) is developing a portfolio of innovative drug candidates with small, focused R&D teams, a model it calls “asset-centric.”

June 20, 2023

Developments

Centessa receives FDA fast track in hemophilia B

The FDA granted fast track designation to Centessa Pharmaceuticals’ (NASDAQ:CNTA) SerpinPC, an investigational novel inhibitor of activated protein C (APC) being developed for the treatment of hemophilia B, with or...

May 22, 2023

Tag - CNTA

Leerink ups Centessa PT to $11 from $6 on pipeline prospects

Centessa focused on asset-centric, patient-centric drug development

Centessa receives FDA fast track in hemophilia B

General

More